The Endothelium and Platelets in Cardiovascular Disease: Potential Targets for Therapeutic Intervention

Tan, K. T.; Watson, S. P.; Lip, G. Y. H.
June 2004
Current Medicinal Chemistry - Cardiovascular & Hematological Age;Jun2004, Vol. 2 Issue 2, p169
Academic Journal
The interaction between platelets and endothelium has been implicated in many disease processes. It is now known that platelets may be involved in the initiation of atheroma, modulate various inflammatory responses, and contribute to endothelial dysfunction, in addition to their classical role in thombosis. Indeed, various drugs targeting platelets and endothelium have been shown to be of benefit in disease states. The last few years has seen an exponential increase in our knowledge of platelet and endothelial biology. As a result of this, many new drugs, for example the ADP-antagonists and the GpIIbIIIa antagonists, have been developed for use in the clinical setting. There is also renewed interest in the use of older drugs (for example, the statins) in modulating plateletendothelial interactions. This review focuses on the recent advances in our understanding of the interaction(s) between platelets and endothelium and how this knowledge could be manipulated for therapeutic gain.


Related Articles

  • Hyperhomocysteinemia and Endothelial Dysfunction. Zhong-Jian Cheng; Xiaofeng Yang; Hong Wang // Current Hypertension Reviews;2009, Vol. 5 Issue 2, p158 

    Hyperhomocysteinemia (HHcy) is a significant and independent risk factor for cardiovascular diseases. Endothelial dysfunction (ED) is the earliest indicator of atherosclerosis and vascular diseases. We and others have shown that HHcy induced ED in human and in animal models of HHcy induced by...

  • Effects of Tadalafil on Platelets and Endothelium in Patients With Erectile Dysfunction and Cardiovascular Risk Factors: A Pilot Study. De Bon, Emiliano; Bonanni, Guglielmo; Saggiorato, Graziella; Bassi, PierFrancesco; Cella, Giuseppe // Angiology;Aug2010, Vol. 61 Issue 6, p602 

    Activation of endothelial cells and platelets is an initial step toward the development of cardiovascular disease. Erectile dysfunction (ED) may be an early manifestation of endotheliopathy. We evaluated the effects of tadalafil on cyclic nucleotides (cGMP and cAMP) and soluble adhesion...

  • Oxidative Stress, Endothelial Dysfunction and Atherosclerosis. Victor, Victor M.; Rocha, Milagros; Sol�, Eva; Ba�uls, Celia; Garcia-Malpartida, Katherine; Hern�ndez-Mijares, Antonio // Current Pharmaceutical Design;9/11/2009, Vol. 15 Issue 26, p2988 

    This review focuses on the role of oxidative processes in atherosclerosis and the cardiovascular diseases (CVD) that can arise as a result. Atherosclerosis represents a state of heightened oxidative stress characterized by lipid and protein oxidation in the vascular wall. Overproduction of...

  • Getting to the heart of a splicing enhancer. Bilbao, Daniel; Valcárcel, Juan // Nature Structural Biology;Jan2003, Vol. 10 Issue 1, p6 

    Deals with the link between splicing efficiency, nitric oxide synthesis and cardiovascular disease. Factor that makes nitric oxide a protective agent against atherosclerosis; Role of polymorphic introns on gene encoding human endothelial cell nitric oxide synthase.

  • Nitric oxide insufficiency and atherothrombosis. Voetsch, Barbara; Jin, Richard; Loscalzo, Joseph // Histochemistry & Cell Biology;Oct2004, Vol. 122 Issue 4, p353 

    Nitric oxide (NO) is a structurally simple compound that participates in a wide range of biological reactions to maintain normal endothelial function and an antithrombotic intravascular milieu. Among its principal effects are the regulation of vascular tone, vascular smooth muscle cell...

  • Platelet Activation in Atherogenesis Associated with Low-Grade Inflammation. Antoniades, Charalambos; Bakogiannis, Constantinos; Tousoulis, Dimitris; Demosthenous, Michael; Marinou, Kyriakoula; Stefanadis, Christodoulos // Inflammation & Allergy - Drug Targets;Dec2010, Vol. 9 Issue 5, p334 

    No abstract available.

  • L-Arginine Analogs -- Inactive Markers or Active Agents in Atherogenesis? Surdacki, Andrzej // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 4, p302 

    Dimethylated L-arginine analogs have been attracting the attention of both basic researchers and clinicians for 15 years since 1992 when Vallance et al. were first to observe several fold elevations of asymmetric and symmetric dimethyl-L-arginine levels (ADMA and SDMA, respectively) in plasma of...

  • Oxidative Stress and Endothelial Dysfunction: Say NO to Cigarette Smoking! Grassi, Davide; Desideri, Giovambattista; Ferri, Livia; Aggio, Annalisa; Tiberti, Sergio; Ferri, Claudio // Current Pharmaceutical Design;8/1/2010, Vol. 16 Issue 23, p2539 

    No abstract available.

  • Vascular Abnormalities in Essential Hypertension. Sudano, Isabella; Roas, Susanne; Noll, Georg // Current Pharmaceutical Design;9/21/2011, Vol. 17 Issue 28, p3039 

    Arterial hypertension is a very common disease and an important risk factor for cardiovascular disease. Patients with arterial hypertension are characterized by functional and structural vascular abnormalities. Vascular endothelium plays a fundamental role in modulating vascular tone and...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics